Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代碼VCYT
公司名稱Veracyte Inc
上市日期Oct 30, 2013
CEOStapley (Marc A)
員工數量824
證券類型Ordinary Share
年結日Oct 30
公司地址6000 Shoreline Court, Suite 300
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94080
電話16502436300
網址https://www.veracyte.com/
公司代碼VCYT
上市日期Oct 30, 2013
CEOStapley (Marc A)